This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ford, J.
Right arrow Articles by Pozniak, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ford, J.
Right arrow Articles by Pozniak, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2004, p. 2388-2393, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2388-2393.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients

Jennifer Ford,1* Marta Boffito,2 Adrian Wildfire,2 Andrew Hill,3 David Back,1 Saye Khoo,1 Mark Nelson,2 Graeme Moyle,2 Brian Gazzard,2 and Anton Pozniak2

Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GF,1 PK Research Ltd., St. Stephen's Centre, Chelsea and Westminster Hospital, London SW10 9NH,2 Roche Products Ltd., Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom3

Received 18 December 2003/ Returned for modification 15 March 2004/ Accepted 29 March 2004

Ritonavir-boosted saquinavir (SQV/r) is currently licensed as a twice-daily regimen. Reducing the pill burden with once-daily dosing may improve adherence. Intracellular concentrations of drugs must be related to the clinical efficacy of protease inhibitors. The aims of the study were to determine the cellular and plasma saquinavir and ritonavir concentrations, to determine the half-lives (t1/2s) of the drugs in each compartment, and to examine relationships between drug accumulation and lymphocyte subset P glycoprotein (P-gp) expression. Venous blood samples from 12 human immunodeficiency virus-infected patients receiving a hard-gel formulation of SQV/r (1,600/100 mg once daily) were collected at 2, 6, 12, and 24 h after dosing. Peripheral blood mononuclear cells were separated by density gradient centrifugation, and P-gp expression was measured by dual-color flow cytometry. Plasma and intracellular (cell-associated) drug concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry. The ratio of the intracellular drug area under the concentration-time curve from 0 to 24 h (AUC0-24 h) to plasma drug AUC0-24 h was calculated to determine cellular drug accumulation. The median (range) AUC0-24 h of saquinavir in plasma was 16.2 (5.7 to 39.3) mg · h · liter–1, and that in cells was 46.3 (24.7 to 114.6) mg · h · liter–1. Corresponding ritonavir values were 7.5 (1.5 to 14.6) mg · h · liter–1 and 10.4 (3.2 to 13.7) mg · h · liter–1, respectively. The median accumulation ratios of cellular AUC to plasma AUC for saquinavir and ritonavir were 3.31 (range, 1.49 to 6.69) and 1.46 (range, 0.83 to 4.15), respectively. Significant differences between the plasma and intracellular saquinavir t1/2s (4.5 h [range, 2.5 to 9.3 h] and 5.9 h [range, 4.0 to 17.7 h]; P = 0.034) and between the plasma and intracellular ritonavir t1/2s (4.1 h [range, 2.6 to 8.3 h] and 6.2 h [range, 3.9 to 18.6 h]; P = 0.032) were observed. No relationship was observed between the accumulation of saquinavir or ritonavir and lymphocyte subset P-gp expression. The intracellular t1/2s of saquinavir and ritonavir were longer than the plasma t1/2s, indicating that intracellular drug may be available at a time when concentrations in plasma are below the minimum effective concentration.

* Corresponding author. Mailing address: Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Pl., Block H, First Floor, Liverpool L69 3GF, United Kingdom. Phone: 0151 794 5565. Fax: 0151 794 5656. E-mail: jford{at}liv.ac.uk.

Antimicrobial Agents and Chemotherapy, July 2004, p. 2388-2393, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2388-2393.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Bickel, M., Bodtlander, A., Knecht, G. K., Stephan, C., von Hentig, N., Kurowski, M., Gute, P., Klauke, S., Lutz, T. (2009). Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. J Antimicrob Chemother 64: 1260-1264 [Abstract] [Full Text]  
  • Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. J Antimicrob Chemother 62: 161-167 [Abstract] [Full Text]  
  • Marin-Niebla, A., Lopez-Cortes, L. F., Ruiz-Valderas, R., Viciana, P., Mata, R., Gutierrez, A., Pascual, R., Rodriguez, M. (2007). Clinical and Pharmacokinetic Data Support Once-Daily Low-Dose Boosted Saquinavir (1,200 Milligrams Saquinavir with 100 Milligrams Ritonavir) in Treatment-Naive or Limited Protease Inhibitor-Experienced Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 51: 2035-2042 [Abstract] [Full Text]  
  • Ford, J., Boffito, M., Maitland, D., Hill, A., Back, D., Khoo, S., Nelson, M., Moyle, G., Gazzard, B., Pozniak, A. (2006). Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother 58: 1009-1016 [Abstract] [Full Text]  
  • Pulido, F., Ribera, E., Moreno, S., Munoz, A., Podzamczer, D., del Pozo, M. A., Rivero, A., Rodriguez, F., Sanjoaquin, I., Teira, R., Viciana, P., Villalonga, C., Antela, A., Carmena, J., Ena, J., Gonzalez, E., Kindelan, J. M., Mallolas, J., Marquez, M., Martinez, E. (2005). Once-daily antiretroviral therapy: Spanish Consensus Statement. J Antimicrob Chemother 56: 808-818 [Abstract] [Full Text]  
  • Almond, L. M., Hoggard, P. G., Edirisinghe, D., Khoo, S. H., Back, D. J. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 56: 738-744 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»